Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Esophageal squamous cell carcinoma (ESCC) exhibits heterogeneous responses to immunotherapy, partly driven by metabolic alterations within the tumor microenvironment. Integrative untargeted metabolomic and single-cell transcriptomic analyses of tumors from patients receiving neoadjuvant anti–PD-1 therapy identified UDP-GlcNAc as a metabolite enriched in non-responders and strongly associated with poor outcomes.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
